In any of these semi-regular "exchanges" the CEO has with certain select shareholders, has he said anything regarding:
- his fund raising efforts?
- how the $5M due to Boniuk in June will impact his Sept 2018 estimated date of insolvency?
- if he's licensed rights from Diwan for the VZV indications, and if not, why?
- how he views the GSK vaccine, with >90% efficacy, affecting the shingles market?
- his estimate of when company will be ready to schedule a pre-IND meeting with the FDA?
If I had the ear of the CEO, I'd sure as hell take the opportunity to ask questions of substance, rather than details about an utterly inconsequential poster presented at a meeting by one of his geriatric cronies.